Anaphore appoints Paul Grayson CEO
This article was originally published in Scrip
Executive Summary
Anaphore has appointed Paul Grayson president and CEO, replacing Dr Katherine Bowdish, a co-founder of Anaphore, who will continue to serve the company as a consultant. Mr Grayson previously served as CEO of Fate Therapeutics, a privately held biopharmaceutical company, and founding chairman and CEO of Senomyx.